Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening for hepatocellular carcinoma.

Morris Sherman1

  • 1University of Toronto and Toronto General Hospital, 200 Elizabeth Street, Toronto, Ont., Canada M5G 2C4. morris.sherman@uhn.on.ca

Best Practice & Research. Clinical Gastroenterology
|March 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.

Gastroenterology·2026
Same author

What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association.

JHEP reports : innovation in hepatology·2022
Same author

Real-world health care utilization in treatment of HCV: Results from the Canadian SIMPLE observational trial.

Canadian liver journal·2022
Same author

Reminiscences of a soon-to-be ex-hepatologist.

Canadian liver journal·2022
Same author

A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma.

Hepatology communications·2022
Same author

The viral hepatitis B care cascade: A population-based comparison of immigrant groups.

Hepatology (Baltimore, Md.)·2021
Same journal

Needle-based confocal laser endomicroscopy and artificial intelligence in pancreatic cystic lesions: Insights and clinical advances.

Best practice & research. Clinical gastroenterology·2026
Same journal

Evidence-based approach to the diagnosis, management and surveillance of pancreatic cystic lesions: from the guidelines to the clinical practice.

Best practice & research. Clinical gastroenterology·2026
Same journal

Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound.

Best practice & research. Clinical gastroenterology·2026
Same journal

Predictive risk models for the diagnosis and cancer progression of pancreatic cysts.

Best practice & research. Clinical gastroenterology·2026
Same journal

Preface.

Best practice & research. Clinical gastroenterology·2026
Same journal

Endoscopic ultrasound-guided treatment of pancreatic lesions.

Best practice & research. Clinical gastroenterology·2026
See all related articles

Currently, no evidence shows screening for hepatocellular carcinoma (HCC) reduces mortality. However, screening may be justified due to potential benefits from treating small cancers, especially with liver transplantation advancements.

Area of Science:

  • Hepatology
  • Oncology
  • Diagnostic Imaging

Background:

  • Hepatocellular carcinoma (HCC) screening is common despite a lack of mortality reduction evidence.
  • Existing literature on HCC screening is often biased by uncontrolled and retrospective studies.
  • The benefits of early cancer detection via screening are debated, particularly concerning treatment efficacy.

Purpose of the Study:

  • To critically evaluate the evidence for hepatocellular carcinoma (HCC) screening.
  • To address the complexities and biases within current HCC screening literature.
  • To provide guidance on the investigation of abnormal screening results.

Main Methods:

  • Literature review focusing on biases in uncontrolled and retrospective studies.
  • Analysis of the rationale for HCC screening in the context of liver transplantation.

Related Experiment Videos

  • Assessment of current guidelines for managing abnormal screening results.

    • Main Results:

    • No definitive evidence currently supports HCC screening reducing mortality.
    • Screening practices are widespread, potentially influenced by perceived benefits of early detection.
    • False-positive screening results are frequent, with inadequate guidance for further investigation.
    • Effective treatment of small HCCs, particularly with liver transplantation, may justify screening.

    Conclusions:

    • HCC screening lacks robust evidence for mortality reduction.
    • The potential benefits of treating small HCCs may justify screening, especially with liver transplantation.
    • Further research is needed to address biases and establish clear protocols for abnormal screening results and follow-up imaging (CT, MRI).